Sterling Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Sterling Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-327	Closed	-$10.9K	–	3404
2026 Q1	$10.9K	Buy	327 +22	+7%	+$863	﹤0.01%	2322
2025 Q4	$14.1K	Buy	305 +204	+202%	+$11.2K	﹤0.01%	2429
2025 Q3	$6.83K	Buy	101 +4	+4%	+$297	﹤0.01%	2665
2025 Q2	$8.13K	Buy	97 +69	+246%	+$5.17K	﹤0.01%	2259
2025 Q1	$2K	Buy	28 +2	+8%	+$97	﹤0.01%	2600
2024 Q4	$1.17K	Buy	26 +3	+13%	+$155	﹤0.01%	2911
2024 Q3	$1.16K	Buy	+23	New	+$1.1K	﹤0.01%	2452

Sterling Capital Management's SLNO Position: Q2 2026 in Review

Sterling Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 327 shares — an estimated $10.9K sold.

Sterling Capital Management first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $14.1K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Sterling Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Sterling Capital Management sold 327 Soleno Therapeutics shares in Q2 2026, an estimated $10.9K.
Sterling Capital Management first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
Sterling Capital Management's Soleno Therapeutics position peaked at $14.1K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.